Jade Biosciences reported a net loss of $55.8 million for Q2 2026, driven by increased R&D expenses to $50.1 million and G&A costs of $8.9 million. The company holds $461.2 million in cash and investments, providing runway into late 2028 following a recent $172.5 million public offering. Clinically, JADE101 showed positive Phase 1 interim data for IgA nephropathy with potential for every-12-week dosing, prompting the start of a Phase 2 trial and plans for a Phase 3 study in early 2027. Dosing began in the Phase 1 rheumatoid arthritis trial for JADE201, while JADE301 is scheduled to enter Phase 1 trials in late 2026. Mark Eisner joined the board of directors. Jade Biosciences is a clinical-stage biotechnology company developing therapies for autoimmune diseases.

Jade Biosciences, Inc. entered into a JADE301 License Agreement with Paragon Therapeutics, Inc. on June 29, 2026, granting them an exclusive, worldwide, sublicensable license to exploit monospecific antibodies targeting an undisclosed target in all therapeutic areas. The agreement includes milestone payments totaling up to $22.0 million, milestone payments of $1.5 million (already paid) and $2.5 million upon first human dosing in Phase 1, and sublicensing fees of up to $20.1 million. The company is obligated to pay Paragon Paragon will pay Paragon a low to mid-single-digit percentage royalty on monospecific products and a mid-single-digit percentage royalty on multispecific products. Jade Biosciences, Inc. is a biotechnology company focused on the development and treatment of human disease and disorders through antibody-based therapies.

Jade Biosciences, Inc. appointed Mark Eisner, M.D., M.P.H., to the Board of Directors as a Class I director and a member of the Nominating and Corporate Governance Committee. Dr. Eisner previously held leadership roles at Vir Biotechnology, Inc., Sonoma Biotherapeutics, Inc., and FibroGen, Inc., and spent 11 years at Genentech, Inc. As part of his appointment, Dr. Eisner will receive an annual cash retainer and a stock option to purchase 47,675 shares of common stock. Jade Biosciences, Inc. is a biotechnology company focused on developing biological products for therapeutic use.

On June 10, 2026, Jade Biosciences, Inc. filed Amended and Restated Articles of Incorporation following stockholder approval at the 2026 Annual Meeting to waive jury trials in certain circumstances. Additionally, the Board adopted Amended and Restated Bylaws effective June 9, 2026, which modernize corporate governance by permitting virtual meetings, updating record date rules for postponed meetings, and revising the voting standard for non-director matters to a simple majority of votes cast. The company also elected Class II Directors Christopher Cain and Tom Frohlich and ratified PricewaterhouseCoopers LLP as its independent auditor. Jade Biosciences is a biotechnology company.